Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)

NCT02895373 is registered in ClinicalTrials.gov with Thomas Staudinger as lead sponsor.

NCT NCT02895373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02895373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)
Lead sponsor
Thomas Staudinger
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2016
Completion date
July 31, 2021
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extracorporeal membrane oxygenation, respiratory distress syndrome, adult